Inotrem Granted Access to Priority Medicines Scheme (PRIME) for Its Lead Compound MOTREM™ in the Treatment of Septic Shock
Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, today announced that the European Medicines Agency (EMA) has granted access to its PRIority MEdicines (PRIME) scheme for its lead product MOTREMTM in the field of septic shock.
The purpose of PRIME created in 2016 by the EMA is to bring treatments to patients faster by providing early and enhanced support to medicines that have the potential to address patients’ unmet needs. Through the PRIME scheme, Inotrem will be able to optimize the development of its lead compound and accelerate EMA’s regulatory assessment. The inclusion of MOTREMTM in the PRIME program was supported by the following criteria: (i) there is an important unmet medical need for the treatment of septic shock, (ii) the efficacy of MOTREMTM could be proven in relevant preclinical models in vivo and (iii) data from a Phase 1 clinical trial showed tolerance in human subjects. Inotrem launched this year a Phase 2 multicenter clinical trial with patients suffering from septic shock in four European countries.
Septic shock is a serious and very debilitating acute condition with high mortality and associated long-term physical, psychological, and cognitive disabilities in survivors. Sepsis, which is characterized by an intense and excessive systemic inflammatory reaction in response to a serious infection, affects worldwide up to 1% of the population annually with a mortality rate of 25 to 40% placing it as the 10th leading cause of death in developed countries and the 1st cause of death in intensive care units. MOTREMTM is the formulation of the active ingredient LR12, a synthetic peptide capable of controlling the amplification loop of the inflammatory response by inhibiting the TREM-1 receptor, and as such brings the potential of improving hemodynamic parameters and survival rates of septic shock patients. There are currently no specific therapies approved for this indication, and Inotrem’s MOTREMTM aims at becoming the first mechanism-based personalized medicine for septic shock.
“EMA’s decision to grant our product the PRIME status is an important recognition of both Inotrem’s innovative therapeutic approach in the management of acute inflammation and the critical need for causal therapies in a severe condition such as septic shock. This is also the first time a product being developed in the critical care setting is receiving the PRIME status,” said Jean-Jacques Garaud, M.D., CEO and co-founder of Inotrem. “We are very pleased to be part of this program and look forward to working together with the EMA’s Committee for Medicinal Products for Human Use with their regulatory support to pursue our clinical development plan moving toward the MOTREM TM marketing authorization process,” added Margarita Salcedo Magguilli, CDO of Inotrem.
Anne REIN, +33 6 03 35 92 05
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Bella Hadid Headlines True Religion’s Latest Campaign20.8.2018 15:32 | Tiedote
True Religion has tapped Bella Hadid to be the face of the brand. The supermodel embodies all things True Religion, past, present and future; iconic, edgy and everlasting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005283/en/ Bella Hadid Headlines True Religion’s Latest Campaign (Photo: Business Wire) An inherit fan of the brand, Bella was the natural choice to meld the iconic essence of the brand with the modern view of its future. An all-star team was assembled including photographer Boo George, stylist Mimi Cuttrell, and hair and makeup duo Jen Atkin and Mary Phillips to create imagery and complementary looks that usher True Religion into a new era that honors the heritage of the brand. A quintessential, confident LA girl with roots at home and abroad, Bella’s voice was not only an inspiration, but an integral part in imagining this campaign, envisioning the brand through her eyes for the next generation of True
FRISS Brings Claim Fraud Analysis to a Next Level With Web-IQ´s Innovative Online Network Solution20.8.2018 14:30 | Tiedote
Asking your neighbor or friend to sign as a witness to a claim for car damages at your insurance company will work no more, with the new Claim Fraud Analysis feature of FRISS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005039/en/ Eldert van Wijngaarden (Web-IQ) and Philip van Waning (FRISS) shaking hands. (Photo: Business Wire) FRISS, the worldwide provider of AI powered fraud and risk solutions for the P&C insurance industry, recently added a new and innovative feature in their fraud analytics solution: Online Network Analysis from Web-IQ. This feature automatically identifies if the claimants and the insured or other involved persons are related to each other in an on-line environment. This is a proven and strong indicator for fraudulent claims. Especially with car accidents and other types of claims where multiple persons are involved, it adds a whole new approach to the traditional claim analyses. “Research sho
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™ (patisiran)20.8.2018 14:30 | Tiedote
Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. “On behalf of the entire Veristat team that has supported Alnylam in the development of this therapy, we are humbled to have contributed towards this first-in-class drug approval for Alnylam, for the patients with hATTR amyloidosis and their families,” said John P. Balser, Ph.D., President and Co-Founder of Veristat. “We are continuing to support Alnylam as they look to expand regulatory approval of this treatment to other regions of the world.” Veristat began working with Alnylam over 11 years ago and helped design the studies and prepare the Investigational New Drug (IND) submission for patisiran. Our collaboration continued throughout the entire patisiran program inclusive of a phase 2 study, a phase 3 pivotal study
Global IBC Future Zone and IABM Future Trends Theatre to Explore the Latest Tech Shaping the Industry20.8.2018 14:18 | Tiedote
IBC2018, the world’s most influential media, entertainment and technology show, today announces the line-up for the IBC Future Zone and IABM Future Trends Theatre. Well established as part of the IBC Exhibition, from 14-18 September, the Future Zone brings together the very latest ideas, innovations and concept technologies from international industry and academia and showcases them in a single specially-curated area sitting alongside exhibition Hall 8. This year, the focus is on showing how new technologies grow from their first inception and progress through to research, development, and validation projects; right through to maturing into the ground-breaking applications and future product standards. Major industry trail-blazers presenting their visions of the future, include Japan’s NHK and BBC R&D from the UK. Both companies will demonstrate a number of technology advances, including: Web-VR applications; object-based media scenarios; pathways to 8K resolution for UHD; and Artifici
Ocean Ambassador of the Netherlands Joins Endowment for Clean Ocean’s Entrepreneur Judges Committee20.8.2018 14:07 | Tiedote
The Endowment for Clean Oceans (ECO) announced Willemijn Peeters, Ocean Ambassador of the Netherlands and the Founding Director of Searious Business has joined ECO’s Entrepreneur Committee that will vet contestants’ plans to remove macro and micro plastics from the world’s oceans. “I am working to solve the problem of what to do with the plastic once it is removed from the ocean, by helping to create a market for plastic recovered from the ocean,” said Peeters. “Just like we need to end the use of single use plastic, we need to replace the manufacture of virgin plastic and replace it with recycled plastics, and as much as possible needs to be plastic recovered from the ocean.” View source version on businesswire.com: https://www.businesswire.com/news/home/20180820005004/en/ Contact information The Endowment for Clean Oceans Daniel Perrin Daniel.Perrin@endowmentforcleanoceans.org or email@example.com
HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)20.8.2018 14:00 | Tiedote
HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence, is proud to announce its participation as an exhibitor at the upcoming 2018 European Society of Cardiology Congress (ESC). The Congress will take place at Messe Munich International in Munich, Germany and will run from August 25 to August 29, 2018. HeartSciences will highlight its MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device as well as recent clinical study results published in the Journal of the American College of Cardiology (JACC) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005047/en/ MyoVista Wavelet ECG 12-Lead Cardiac Testing Device (Photo: Business Wire) The JACC article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presented the results from the investigator-initiated clinical study that focus
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme